Etravirine (ETR) is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) specifically designed for treatment-experienced patients infected with HIV-1. Its unique strength over other, older agents in the NNRTI class is its higher genetic barrier to resistance, allowing it to be used effectively in patients with limited treatment options. The arrival of ETR in the market has made sequential NNRTI therapy possible for the first time in the history of HIV treatment, as it can maintain virologic activity in the presence of certain (and sometimes multiple) NNRTI mutations. Although ETR has demonstrated efficacy in treatment-experienced and NNRTI-resistant patients in large trials, further analyses on its resistance profile are ongoing. As new data emerge on the weighting of ETR’s resistance-associated mutations (RAMs), investigators and clinicians will no doubt be able to further characterize its specific place in the HIV treatment armamentarium.
US Department of Health and Human Services.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines . Accessed January 15, 2009.
2.
Hammer SM, Eron JJ, Reiss P., et al, and the International AIDS Society-USA.Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. J Am Med Assoc.2008;300(5):555-570.
3.
Carr A., Vella S., de Jong MD, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS. 1996;10(6):635-641.
4.
Zhu QY, Scarborough A., Polsky B., Chou TCDrug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains . AIDS Res Hum Retroviruses. 1996;12(6):507-517.
5.
Basavapathruni A., Bailey CM, Anderson KSDefining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J Biol Chem . 2004;279(8):6221-6224.
6.
Staszewski S. , Morales-Ramirez J., Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New Engl J Med . 1999;341(25):1865-1873.
7.
Shafer RW, Smeaton LM, Robbins GK, et al, for the AIDS Clinical Trials Group 384 Team.Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. New Engl J Med.2003;349(24):2304-2315.
8.
Squires K., Lazzarin A., Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr . 2004;36(5):1011-1019.
9.
Riddler S., Haubrich R., DiRienzo G., et al, and the AIDS Clinical Trials Group Study A5142 Team.Class-sparing regimens for initial treatment of HIV-1 infection. New Engl J Med. 2008; 358(20):2095-2106.
10.
Bacheler L. , Jeffrey S., Hanna G., et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001;75(11):4999-5008.
11.
Antinori A. , Zaccarelli M., Cingolani A., et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses. 2002;18(12):835-838.
12.
Delaugerre C. , Rohban R., Simon A., et al. Resistance profile and cross-resistance of HIV-1 among patients failing a nonnucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol. 2001;65(3):445-448.
13.
Frentz D., Van de Vijver Damc, Wensing AMJ, et al. Worldwide comparison of mutational patterns in studies on transmission of drug resistant HIV-1 across the world: update on the results of the WATCH study. 6th European HIV Drug Resistance Workshop ; March 26-28, 2008; Budapest, Hungary. Abstract 4.
14.
Andries K., Azijn H., Thielemans T., et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother . 2004;48(12):4680-4686.
15.
Shehu-Xhilaga M., Tachedjian G., Crowe SM, Kedzierska K.Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. Curr Med Chem. 2005;12(15):1705-1719. 16. Udier-Blagovic M., Tirado-Rives J., Jorgensen WLValidation of a model for the complex of HIV-1 reverse transcriptase inhibitor TMC125 . J Am Chem Soc.2003;125(20):6016-6017.
Kohlstaedt LA, Wang J., Friedman JM, Rice PA, Steitz TACrystal structure of 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992;256(5065):1783-1790.
18.
Das K., Clark AD, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004;47(10):2550-2560.
19.
Vingerhoets J., Azijn H., Fransen E., et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments . J Virol. 2005 ;79(20): 12773-12782.
20.
Gruzdev B., Rakhmanova A., Doubovskaya E., et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day mono-therapy in antiretroviral naïve, HIV-1 infected subjects . AIDS. 2003;17(17):2487-2494.
21.
Gazzard BG, Pozniak AL, Rosenbaum W., et al. An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS. 2003;17(18):49-54.
22.
Hirschel B. , Perneger T.No patient left behind-better treatments for resistant HIV infection. Lancet. 2007;370(9581):3-5.
23.
Scholler M., Hoetelmans R., Beets G., et al. Substantial improvement of oral bioavailability of TMC125 using new tablet formulations in healthy volunteers. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment ; July 24-27, 2005; Rio de Janeiro, Brazil. Abstract TuPe3.1B11.
24.
Bilello JA, Bilello K., Stellrecht J., et al. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type I protease. Antimicrob Agents Chemother. 1996;40(6):1491-1497.
25.
Schöller-Gyüre M., Leemans R., Beets G., et al. Effect of food on the oral bioavailability of the phase III formulation of TMC125. 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20-22, 2006; Lisbon, Portugal. Abstract 80.
26.
Raoof A., Mannens G., Mamidi R., et al. In vivo metabolism and mass balance of the anti-HIV compound TMC125 in laboratory animals and healthy volunteers. AAPS Journal. 2006; 8(suppl 2):M1342.
27.
Schöller-Gyüre M., van den Brink W., Kakuda TN, et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol.2008;48(3):322-329.
28.
Kakuda TN, Schöller-Gyüre M., Woodfall BJ, et al. TMC125 in combination with other medications: summary of drug-drug interactions. 8th International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, Scotland. Abstract PL5.2.
29.
Schöller M., Kraft M., Hoetelmans R., et al. Significant decrease in TMC125 exposures when co-administered with tipranavir boosted with ritonavir in healthy subjects . 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO . Abstract 583.
30.
Scholler-Gyure M., Woodfall B., Bollen S., Peeters M., Vandermuelen K., Hoetelmans R.Pharmacokinetics (pK) of amprenavir (APV) and TMC125 in HIV-infected volunteers receiving TMC125 with fosamprenavir/ritonavir (fosAPV/RTV). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA. Abstract A-370.
Woodfall B. , Vingerhoets J., Peeters M., Peeters I., De Smedt G., Miralles GDImpact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus 2 NRTIs in study TMC125-227. 8th International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, Scotland. Abstract PL5.6.
33.
Ruxrungtham K., Pedro RJ, Latiff GH, et al, for the TMC125C227 study group.Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med.2008;9(10):883-896.
34.
Nadler JP, Berger DS, Blick G., et al, for the TMC125-C223 Writing Group.Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS. 2007 ;21(6):F1-F10.
35.
Cohen C., Steinhart C., Ward D., Ruane P., Peeters M., Woodfall B.48-week durable efficacy and safety results of TMC125 in HIV patients with NNRTI and PI resistance: study TMC125-C223. 12th British HIV Association Annual Spring Conference; 2006 ; Brighton, UK. Abstract P2.
36.
Cohen C., Steinhart CR, Ward DJ, et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. 16th International AIDS Conference ; August 13-18, 2006; Toronto, Canada. Abstract TUPE0061.
37.
Boffito M., Winston A., Jackson A., et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS. 2007;21(11):1449-1455.
38.
Clotet B., Bellos N., Molina JM, et al, for the POWER 1 and 2 study groups.Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568):1169-1178.
39.
Haubrich R. , Cahn P., Grinsztejn, et al. DUET-1: Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA . Abstract 790.
40.
Johnson M., Campbell T., Clotet B., Katlama C., Lazzarin A., Towner W.DUET-2: Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 791.
41.
Lazzarin A. , Campbell T., Clotet B., et al, for the DUET-1 study group.Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):39-48.
42.
Madruga JV, Cahn P., Grinsztejn B., et al, for the DUET-1 study group.Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):29-38.
43.
Trottier B. , Johnson M., Katlama C., et al. Pooled 48-week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients. 17th Annual Canadian Conference on HIV/AIDS Research; April 24-27, 2008; Montreal, Canada. Abstract P167.
44.
Gebo K., Martin S., Corbett C., De Smedt G.Impact of etravirine on hospitalizations and hospital-related costs: 48-week findings from pooled DUET trials. 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico. Abstract TUPE0237.
45.
Yazdanpanah Y. , Fagard C., Descamps D., et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial . 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico. Abstract THAB0406.
46.
Vingerhoets J., Peeters M., Corbett C., et al. Effect of baseline resistance on the virologic response to a novel NNRTI, TMC125, in patients with extensive NNRTI and PI resistance: analysis of study TMC125-C223. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Abstract 154.
47.
Vingerhoets J., Buelens A., Peeters M., et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. 16th International HIV Drug Resistance Workshop; June 12-16, 2007; Barbados, West Indies. Abstract 32.
48.
Geretti AMShifting paradigms: the resistance profile of etravirine. J Antimicrob Chemother. 2008;62(4):643-647.
49.
Vingerhoets J. , Peeters M., Azijn H., et al. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. 17th International HIV Drug Resistance Workshop; June 10-14, 2008; Sitges, Spain. Abstract 24.
50.
Vingerhoets J. , Janssen K., Welkenhuysen-Gybels J., et al. Impact of baseline K103N or Y181C on the virological response to the NNRTI TMC125: analysis of study TMC125-C223. 15th International HIV Drug Resistance Workshop; June 13-17, 2006; Sitges , Spain. Poster 17.
51.
Schapiro JM , Vingerhoets J., Nijs S., et al. Combined PI and NNRTI resistance analysis of the pooled DUET trial: Towards a regimen-based resistance interpretation . 6th European HIV Drug Resistance Workshop; March 26-28, 2008 ; Budapest, Hungary. Abstract 46.
52.
Su G., Li Y., Paul A., et al. In vitro selection and characterization of viruses resistant to R1206, a novel non-nucleoside reverse transcriptase inhibitor. 16th International HIV Drug Resistance Workshop; June 12-16, 2007; Barbados; Abstract 33.
53.
Haubrich R. , Schapiro JM, Vingerhoets J., et al. Combined darunavir and etravirine resistance analysis of the pooled DUET trials: when can we spare the other new classes?17th International AIDS Conference ; August 3-8, 2008; Mexico City, Mexico. Abstract TUPE0048.
54.
Llibre JM, Santos JR, Puig T., Molto J., Ruiz I., Clotet B.Prevalence of mutations with impact on virological response to etravirine in routine clinical samples. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008 ; Boston, MA. Poster 868.
55.
Kagan RM, Sista P., Pattery T., Bacheler L., Schwab DA. Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples. AIDS.2009;23(12):1602-1605.
56.
Borrás-Blasco J., Navarro-Ruiz A., Borrás C., Casterá E.Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother.2008 ;62(5):879-888.
57.
The FDA Safety Information and Adverse Event Reporting Program.Intelence (Etravirine) Posted 08/27/2009 . www.hhs.gov.
